Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.

NMR UPLC-MS lipidomics metabolomics non-small-cell-lung cancer overall survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Jul 2020
Historique:
received: 09 06 2020
revised: 01 07 2020
accepted: 10 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 28 7 2020
Statut: epublish

Résumé

The metabolic requirements of metastatic non-small cell lung (mNSCLC) tumors from patients receiving first-line platinum-doublet chemotherapy are hypothesized to imprint a blood signature suitable for survival prediction. Pre-treatment samples prospectively collected at baseline from a randomized phase III trial were assayed using nuclear magnetic resonance (NMR) spectroscopy (

Identifiants

pubmed: 32708705
pii: cancers12071926
doi: 10.3390/cancers12071926
pmc: PMC7409233
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : R21-CA-213234
Pays : United States
Organisme : Canadian Cancer Society
ID : 704970

Références

Biochem J. 2012 Feb 1;441(3):789-802
pubmed: 22248339
Respiration. 1995;62(4):223-7
pubmed: 8578019
World J Biol Chem. 2014 Feb 26;5(1):68-74
pubmed: 24600515
J Clin Oncol. 2005 Apr 20;23(12):2831-9
pubmed: 15837997
PLoS One. 2010 May 28;5(5):e10883
pubmed: 20526369
Anal Chem. 2006 Jul 1;78(13):4430-42
pubmed: 16808451
Biochim Biophys Acta. 2013 May;1830(5):3143-53
pubmed: 22995213
Cancer. 1996 Aug 1;78(3):416-21
pubmed: 8697385
Lung Cancer. 2017 Dec;114:70-78
pubmed: 29173770
Lung Cancer. 2011 Nov;74(2):284-92
pubmed: 21411176
J Pharm Biomed Anal. 2014 Nov;100:369-380
pubmed: 25213261
Clin Cancer Res. 2018 May 1;24(9):2100-2109
pubmed: 29437793
Mol Cell. 2016 Jan 21;61(2):210-21
pubmed: 26774282
Oncotarget. 2016 Mar 15;7(11):12904-16
pubmed: 26883203
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Crit Rev Oncol Hematol. 2017 Apr;112:31-40
pubmed: 28325263
Nat Rev Genet. 2014 May;15(5):293-306
pubmed: 24662220
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Cancer Cell. 2015 Feb 9;27(2):211-22
pubmed: 25620030
Nat Protoc. 2007;2(11):2692-703
pubmed: 18007604
Sci Rep. 2015 Feb 25;5:8607
pubmed: 25712604
Lung Cancer. 2010 Apr;68(1):44-50
pubmed: 19559498
Am J Clin Nutr. 2002 Dec;76(6):1244-8
pubmed: 12450889
Future Oncol. 2010 Oct;6(10):1603-24
pubmed: 21062159
Br J Cancer. 2017 Jun 6;116(12):1499-1504
pubmed: 28472819
Metabolomics. 2016;12:58
pubmed: 27073350
Adv Genet. 2010;70:27-56
pubmed: 20920744

Auteurs

Desirée Hao (D)

Department of Medical Oncology, Tom Baker Cancer Centre and Cummings School of Medicine, University of Calgary, 1331-29th Street N.W., Calgary, AB T2N 4N2, Canada.

Arjun Sengupta (A)

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.

Keyue Ding (K)

Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.

E R Ubeydullah (ER)

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.

Saikumari Krishnaiah (S)

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.

Natasha B Leighl (NB)

University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.

Frances A Shepherd (FA)

University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.

Lesley Seymour (L)

Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.

Aalim Weljie (A)

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.

Classifications MeSH